(HealthDay)—For patients with Alzheimer's disease, treatment with the small-molecule γ-secretase inhibitor semagacestat does not improve cognitive status and is associated with worsening of cognitive function, according to a study published in the July 25 issue of the New England Journal of Medicine.
↧